title: Localized ultrasound enhances delivery of rapamycin from microbubbles to prevent smooth muscle proliferation.
abstract: Microbubble contrast agents have been shown to enhance reagent delivery when activated by ultrasound. We hypothesized that ultrasound would enhance delivery of rapamycin, an antiproliferative agent, from the shell of microbubbles, thus reducing proliferation of vascular smooth muscle cells. Our objective was to determine optimal ultrasound parameters that maximized therapeutic efficacy, maintained cell adherence, and minimized the drug exposure time. In vitro assays determined that ultrasound (1 MHz, 0.5% duty cycle) is required to successfully deliver rapamycin from microbubbles and reduce proliferation. Co-injection of rapamycin with control microbubbles did not result in a reduction in proliferation. Successful reduction in proliferation (>50%) required pulses at least 10 cycles in length and at least 300 kPa peak negative pressure at which point 90% of cells remained adherent. The anti-proliferative effect was also localized within a 6mm wide zone by focusing the ultrasound beam.
authors.affiliation: Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.
authors.forename: Linsey C
authors.initials: LC
authors.lastname: Phillips
authors.forename: Alexander L
authors.initials: AL
authors.lastname: Klibanov
authors.forename: Brian R
authors.initials: BR
authors.lastname: Wamhoff
authors.forename: John A
authors.initials: JA
authors.lastname: Hossack
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D045423:Microbubbles; D008858:Microscopy, Phase-Contrast; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D015612:Phonophoresis; D051381:Rats; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D020123:Sirolimus